A potential new treatment for osteoporosis
Nature Medicine
February 8, 2010
Blocking the synthesis of serotonin could treat osteoporosis, according to a report published this week in Nature Medicine.
Osteoporosis is a disease of low bone mass often caused by excessive loss and poor formation of bones. Serotonin is best known for its role as a brain neurotransmitter, but this molecule is also produced by the gut and inhibits bone formation.
Gerard Karsenty and his colleagues tested whether blocking serotonin biosynthesis could treat osteoporosis by increasing bone formation. The researchers developed an inhibitor of tryptophan hydroxylase, a key enzyme in serotonin biosynthesis, and administered it once daily for up to six weeks to mice and rats with osteoporosis. They found that their compound both prevented and treated osteoporosis through an increase in bone formation.
The current treatment for osteoporosis, which acts by promoting bone formation, is the daily injection of parathyroid hormone. The results of this study highlight the potential of serotonin-synthesis blockers as a new generation of drugs to fight osteoporosis.
doi: 10.1038/nm.2098
Research highlights
-
Jun 24
Palaeontology: It sucked to be the prey of ancient cephalopodsScientific Reports
-
Jun 24
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
Jun 23
Scientific community: Women credited less than men in scientific paper authorshipNature
-
Jun 17
Health technology: New cost-effective smartphone test for middle ear functionCommunications Medicine
-
Jun 17
Conservation: Feral cats pushing critically endangered marsupial further towards extinctionScientific Reports
-
Jun 16
Microbiology: DNA analysis indicates origins of the Black DeathNature